8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Feb 25, 2010)

Filed February 25, 2010For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K report on February 25, 2010, primarily to announce its financial results for the fiscal quarter and full year ended December 31, 2009. This filing provides investors with an update on the company's financial performance and operational status as of the end of 2009. The key information is contained within the press release furnished as Exhibit 99.1, which details the company's revenue, expenses, and net income/loss for the reported periods. While the 8-K itself is a brief regulatory filing, the attached press release is crucial for understanding Alnylam's financial health and progress. Investors would look to this announcement for insights into the company's cash burn rate, its progress in drug development, and its overall financial stability as it navigates the competitive landscape of the biotechnology sector.

Key Highlights

  • 1Alnylam Pharmaceuticals reported its Q4 and full-year 2009 financial results on February 25, 2010.
  • 2The filing is an 8-K Current Report, primarily serving to announce financial performance.
  • 3The detailed financial results are provided in a press release furnished as Exhibit 99.1.
  • 4The report covers the financial condition and results of operations for the period ending December 31, 2009.
  • 5This filing is essential for investors seeking an update on Alnylam's financial standing at the close of 2009.
  • 6The information provided is for informational purposes and is not deemed 'filed' for certain SEC purposes unless expressly incorporated by reference.

Frequently Asked Questions

The main purpose of this 8-K filing by Alnylam Pharmaceuticals on February 25, 2010, is to announce and provide the company's financial results for the fourth quarter and the full fiscal year ended December 31, 2009.

The detailed financial information is contained within the press release dated February 25, 2010, which is furnished as Exhibit 99.1 to this Form 8-K.

This specific 8-K filing is primarily focused on financial results. While the accompanying press release (Exhibit 99.1) might briefly mention operational highlights, a deeper dive into drug development progress would typically be found in other company communications or SEC filings like 10-Q or 10-K reports.

This statement means that while the information is publicly disclosed via the 8-K, it is not subject to the same level of liability under Section 18 of the Securities Exchange Act of 1934 as officially 'filed' documents. It also means it won't be automatically incorporated into registration statements unless specifically referenced.